Valo and Montai Agree to Merge Drug Discovery Platforms

Company Valo Health; Montai Therapeutics Event Type Merger Modality AI-enabled small molecule discovery Asset MTAI-1025; oral STAT6 inhibitor program Target NRF2; STAT6 Disease Area Immunology (ulcerative colitis) Summary Valo Health and Montai Therapeutics announced November 11 that they will merge under the Valo name. The…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *